Our findings indicate that miR-182 may promote cell proliferation and migration in TNBC possible via down-regulation of FOXF2. miR-182 may serve as a potential target in TNBC treatment.
Our previous clinical study demonstrated that the under-expression of FOXF2 is associated with early-onset metastasis and poor prognosis of patients with triple-negative breast cancer.
Taken together, we conclude that decreased FOXF2 expression indicates the early-onset metastasis and poor prognosis for patients with histological grade II and triple-negative breast cancer.